Skip to content

    Semaglutide versus liraglutide: what the STEP 8 trial actually studied

    Semaglutide versus liraglutide: what the STEP 8 trial actually studied

    You've probably seen two medications compared in a headline and wondered what that means for you. STEP 8 is a useful place to slow down. It compared semaglutide and liraglutide directly, in the same study, but its results describe a particular group of people under particular conditions. They don't tell you which treatment is right for every person.

    Here's what the researchers looked at, what they found, and what to keep in mind when you come across the numbers.

    The question behind the study

    Both semaglutide and liraglutide act on GLP-1 receptors, which are involved in appetite and other body processes. The STEP 8 researchers wanted to compare changes in body weight with weekly injectable semaglutide and daily injectable liraglutide when both were used alongside nutrition and physical activity counseling.

    That's more informative than looking at two unrelated studies and assuming their results are directly comparable. Separate studies can enroll different people, last different lengths of time, and offer different levels of support. A head-to-head trial gives the comparison a shared setting, although it still has limitations.

    The trial was funded by Novo Nordisk, the manufacturer of both medications. Knowing who funded research is useful context when reading any study.

    Who took part?

    The researchers enrolled 338 adults with overweight or obesity who did not have diabetes. Participants were randomly assigned to receive semaglutide, liraglutide, or a matching placebo. The trial ran for 68 weeks, with follow-up afterward.

    People in both medication groups received individual counseling about food and physical activity. The results therefore reflect medication used with that support, not medication tested in isolation. Roughly four out of five participants were women, and the average participant was about 49 years old. A study group never represents every person who might consider treatment.

    Participants and researchers knew whether a person was in the semaglutide or liraglutide part of the trial. The comparison with each medication's matching placebo used blinding. That distinction matters: a head-to-head comparison is valuable, but knowing which active medication someone receives can affect expectations and experiences.

    What did the weight results show?

    At week 68, the estimated average change from starting weight was a loss of 15.8% in the semaglutide group and 6.4% in the liraglutide group. The pooled placebo groups had an average decrease of 1.9%. The estimated difference between the two active treatments was 9.4 percentage points.

    An average is a summary, not an individual forecast. For a simple illustration, 10% of a 200-pound starting weight is 20 pounds. That doesn't mean a particular person at that weight will lose 20 pounds, or that everyone in a study group had the same result. People respond differently, and changes can vary over time.

    The study also reported how many participants reached several weight-loss thresholds. Those results help show the range behind an average, but even a result achieved by many people is not a promise for the next person who starts treatment.

    The medication details matter

    The trial compared specific injectable regimens: semaglutide given weekly, with a target dose of 2.4 mg, and liraglutide given daily, with a target dose of 3.0 mg. Those are descriptions of the study, not directions for starting or changing medication. Participants followed a dose-escalation schedule in the trial.

    The difference between a daily and weekly routine may matter to someone choosing a treatment. So can cost, coverage, access, prior response and how well a medicine is tolerated. A result from one study cannot settle those questions on its own.

    The comparison also doesn't cover every formulation, dose, or treatment plan. If you see the STEP 8 numbers used in an advertisement or social post, check whether the product being discussed is actually the one studied.

    What about side effects and staying on treatment?

    Digestive side effects were commonly reported in both active-treatment groups. About 84% of people in the semaglutide group and 83% in the liraglutide group reported a gastrointestinal adverse event during the trial. Those figures count reports during a lengthy study; they do not mean everyone had the same symptom or severity.

    Some participants stopped their assigned treatment before the end. At the end of treatment, 271 of the 338 randomized participants were still on it; 319 completed the trial's follow-up. Finishing a study visit and continuing a medication for the entire study are different things, and both numbers help explain what happened.

    If side effects are disrupting meals, fluids, sleep, or daily activities, bring that up with your prescriber. Ask what information they need from you and what the next step should be. Don't change your prescribed plan based on a study headline.

    A better way to use the comparison

    STEP 8 gives clinicians and patients one piece of useful evidence: under the conditions studied, the weekly semaglutide group had a greater average weight reduction than the daily liraglutide group. It doesn't tell you exactly how you will respond, which side effects you will have, or whether either treatment fits your health history.

    For your next appointment, try turning the headline into a practical question: “How relevant is this study to my situation, and what would we consider when choosing a treatment?” That conversation can account for your goals and the details a group average can't see.